Anne E Cust

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4948322/publications.pdf

Version: 2024-02-01

201 papers	7,798 citations	57719 44 h-index	60583 81 g-index
207 all docs	207 docs citations	207 times ranked	10662 citing authors

#	Article	IF	Citations
1	Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF). JAMA Dermatology, 2022, 158, 33.	2.0	26
2	Effect of an interactive educational activity using handheld ultraviolet radiation dosimeters on sun protection knowledge among Australian primary school students. Preventive Medicine Reports, 2022, 25, 101690.	0.8	1
3	Early detection of skin cancer in Australia â€“ current approaches and new opportunities. Public Health Research and Practice, 2022, 32, .	0.7	9
4	Sentinel lymph node biopsy rates in Victoria, 2018 and 2019. Medical Journal of Australia, 2022, 217, 208-209.	0.8	3
5	Protocol for the implementation of a stepped-care model to address fear of cancer recurrence in patients previously diagnosed with early-stage (0â€“II) melanoma. BMJ Open, 2022, 12, e054337.	0.8	2
6	Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040. JAMA Dermatology, 2022, 158, 495.	2.0	254
7	Independent evaluation of melanoma polygenic risk scores in <scp>UK</scp> and Australian prospective cohorts*. British Journal of Dermatology, 2022, 186, 823-834.	1.4	10
8	Sensitivity of two Australian melanoma risk tools to identify highâ€risk individuals among people presenting with their first primary melanoma. Australasian Journal of Dermatology, 2022, , .	0.4	0
9	Systematic development of quality indicators for skin cancer management in primary care: a mixed-methods study protocol. BMJ Open, 2022, 12, e059829.	0.8	2
10	Precision Public Health Initiatives in Cancer: Proceedings from the Transdisciplinary Conference for Future Leaders in Precision Public Health. BMC Proceedings, 2022, 16, .	1.8	0
11	Experiences of Patient-Led Surveillance, Including Patient-Performed Teledermoscopy, in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study. JMIR Dermatology, 2022, 5, e35916.	0.4	3
12	FRAMe: Familial Risk Assessment of Melanomaâ€”a risk prediction tool to guide CDKN2A germline mutation testing in Australian familial melanoma. Familial Cancer, 2021, 20, 231-239.	0.9	6
13	Melanomas and stress patterns on the foot: A systematic review and meta-analysis. Journal of the American Academy of Dermatology, 2021, 85, 256-258.	0.6	5
14	A different finding on whether naevus numbers change during adulthood. British Journal of Dermatology, 2021, 184, 193-193.	1.4	1
15	Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity*. British Journal of Dermatology, 2021, 184, 1085-1093.	1.4	13
16	An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study. British Journal of Dermatology, 2021, 184, 957-960.	1.4	3
17	Knowledge and attitudes of Australian dermatologists towards sentinel lymph node biopsy for melanoma: a mixed methods study. Australasian Journal of Dermatology, 2021, 62, 168-176.	0.4	3
18	Prevalence of skin examination behaviours among Australians over time. Cancer Epidemiology, 2021, 70, 101874.	0.8	11

#	Article	IF	Citations
19	Differences in Melanoma Between Canada and New South Wales, Australia: A Population-Based Genes, Environment, and Melanoma (GEM) Study. JID Innovations, 2021, 1, 100002.	1.2	1
20	Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. Annals of Oncology, 2021, 32, 375-383.	0.6	25
21	Genomic Risk Score for Melanoma in a Prospective Study of Older Individuals. Journal of the National Cancer Institute, 2021, 113, 1379-1385.	3.0	14
22	Birth cohort-specific trends of sun-related behaviors among individuals from an international consortium of melanoma-prone families. BMC Public Health, 2021, 21, 692.	1.2	4
23	Diagnostic tools used for melanoma: A survey of Australian general practitioners and dermatologists. Australasian Journal of Dermatology, 2021, 62, 300-309.	0.4	4
24	Changes in sun protection behaviours, sun exposure and shade availability among adults, children and adolescents in New South Wales, 2003â€“2016. Australian and New Zealand Journal of Public Health, 2021, 45, 462-468.	0.8	7
25	Can patient-led surveillance detect subsequent new primary or recurrent melanomas and reduce the need for routinely scheduled follow-up? A protocol for the MEL-SELF randomised controlled trial. Trials, 2021, 22, 324.	0.7	10
26	Acceptability of riskâ€stratified population screening across cancer types: Qualitative interviews with the Australian public. Health Expectations, 2021, 24, 1326-1336.	1.1	20
27	School-based interventions to improve sun-safe knowledge, attitudes and behaviors in childhood and adolescence: A systematic review. Preventive Medicine, 2021, 146, 106459.	1.6	15
28	Efficiency of Detecting New Primary Melanoma Among Individuals Treated in a High-risk Clinic for Skin Surveillance. JAMA Dermatology, 2021, 157, 521.	2.0	25
29	526 Functional, inherited vitamin D-binding protein variants associated with mortality among melanoma patients. Journal of Investigative Dermatology, 2021, 141, S92.	0.3	0
30	Advancing precision public health using human genomics: examples from the field and future research opportunities. Genome Medicine, 2021, 13, 97.	3.6	26
31	Identifying the â€˜Active Ingredients' of an Effective Psychological Intervention to Reduce Fear of Cancer Recurrence: A Process Evaluation. Frontiers in Psychology, 2021, 12, 661190.	1.1	4
32	Health utilities for nonâ€melanoma skin cancers and preâ€cancerous lesions: A systematic review. Skin Health and Disease, 2021, 1, e51.	0.7	5
33	Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: A crossâ€sectional survey of health professionals. Clinical Genetics, 2021, 100, 430-439.	1.0	15
34	Surveillance of patients with thin melanoma. Australasian Journal of Dermatology, 2021, 62, 530-532.	0.4	0
35	Strengthening melanoma prevention and early detection among people with type 2 diabetes. British Journal of Dermatology, 2021, 185, 692-693.	1.4	0
36	Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis. Melanoma Research, 2021, 31, 482-486.	0.6	9

#	Article	IF	Citations
37	Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial. Genetics in Medicine, 2021, 23, 2394-2403.	1.1	22
38	Comparison of community pathologists with expert dermatopathologists evaluating Breslow thickness and histopathologic subtype in a large international population-based study of melanoma. JAAD International, 2021, 4, 25-27.	1.1	3
39	Mendelian Randomization in Cardiovascular Research. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e005623.	0.9	9
40	â€˜There is a lot of good in knowing, but there is also a lot of downsâ€™: public views on ethical considerations in population genomic screening. Journal of Medical Ethics, 2021, 47, e28-e28.	1.0	7
41	Disease-Associated Risk Variants in ANRIL Are Associated with Tumor-Infiltrating Lymphocyte Presence in Primary Melanomas in the Population-Based GEM Study. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2309-2316.	1.1	2
42	Association Between Melanoma Detected During Routine Skin Checks and Mortality. JAMA Dermatology, 2021, 157, 1425.	2.0	27
43	Germline variants are associated with increased primary melanoma tumor thickness at diagnosis. Human Molecular Genetics, 2021, 29, 3578-3587.	1.4	3
44	Association of Melanoma-Risk Variants with Primary Melanoma Tumor Prognostic Characteristics and Melanoma-Specific Survival in the GEM Study. Current Oncology, 2021, 28, 4756-4771.	0.9	1
45	Benefits of a brief psychological intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: 12â€month followâ€up results of a randomized controlled trial. British Journal of Dermatology, 2020, 182, 860-868.	1.4	13
46	Development and external validation study of a melanoma risk prediction model incorporating clinically assessed naevi and solar lentigines. British Journal of Dermatology, 2020, 182, 1262-1268.	1.4	12
47	Inherited Melanoma Risk Variants Associated with Histopathologically Amelanotic Melanoma. Journal of Investigative Dermatology, 2020, 140, 918-922.e7.	0.3	1
48	A risk prediction model for the development of subsequent primary melanoma in a populationâ€based cohort. British Journal of Dermatology, 2020, 182, 1148-1157.	1.4	28
49	MC1R variants and associations with pigmentation characteristics and genetic ancestry in a Hispanic, predominately Puerto Rican, population. Scientific Reports, 2020, 10, 7303.	1.6	9
50	Multiplex melanoma families are enriched for polygenic risk. Human Molecular Genetics, 2020, 29, 2976-2985.	1.4	9
51	å¼€å•ä¸€ç§æ–°°æ–¹³æ¥è®¡ç®—ä¸ªä½“çš„é»‘è‰²ç´ é£Žé™©. British Journal of Dermatology, 2020, 182, e177	1.4	0
52	Association of Known Melanoma Risk Factors with Primary Melanoma of the Scalp and Neck. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2203-2210.	1.1	6
53	Development of a new method to calculate individualsâ€™ melanoma risk. British Journal of Dermatology, 2020, 182, e166.	1.4	0
54	Early detection of melanoma: a consensus report from the Australian Skin and Skin Cancer Research Centre Melanoma Screening Summit. Australian and New Zealand Journal of Public Health, 2020, 44, 111-115.	0.8	30

#	Article	IF	Citations
55	Identifying challenges to implementation of clinical practice guidelines for sentinel lymph node biopsy in patients with melanoma in Australia: protocol paper for a mixed methods study. BMJ Open, 2020, 10, e032636.	0.8	6
56	Implementation considerations for offering personal genomic risk information to the public: a qualitative study. BMC Public Health, 2020, 20, 1028.	1.2	11
57	The Melanoma Genomics Managing Your Risk Study randomised controlled trial: statistical analysis plan. Trials, 2020, 21, 594.	0.7	5
58	Longâ€term deaths from melanoma according to tumor thickness at diagnosis. International Journal of Cancer, 2020, 147, 1391-1396.	2.3	16
59	Association of <scp>IRF</scp> 4 singleâ€nucleotide polymorphism rs12203592 with melanomaâ€specific survival. British Journal of Dermatology, 2020, 183, 163-165.	1.4	6
60	Who dies from thin melanoma?. British Journal of Dermatology, 2020, 182, 827-828.	1.4	1
61	Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility. Nature Genetics, 2020, 52, 494-504.	9.4	138
62	Geneâ€“environment interactions and melanoma risk. British Journal of Dermatology, 2020, 183, 205-206.	1.4	2
63	Australian general practitionersâ€™ attitudes and knowledge of sentinel lymph node biopsy in melanoma management. Australian Journal of General Practice, 2020, 49, 355-362.	0.3	3
64	GPsâ€™ involvement in diagnosing, treating, and referring patients with suspected or confirmed primary cutaneous melanoma: a qualitative study. BJGP Open, 2020, 4, bjgpopen20X101028.	0.9	11
65	Molecular Epidemiology of Melanoma. , 2020, , 451-469.		0
66	Personalized melanoma risk assessments and tailored prevention advice: a pragmatic randomized controlled trial in Australian general practice. Family Practice, 2019, 36, 237-246.	0.8	7
67	Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. Journal of the American Academy of Dermatology, 2019, 81, 386-394.	0.6	17
68	Cost-Effectiveness of a Psycho-Educational Intervention Targeting Fear of Cancer Recurrence in People Treated for Early-Stage Melanoma. Applied Health Economics and Health Policy, 2019, 17, 669-681.	1.0	11
69	Emotional and behavioural reactions to melanoma genomic risk information. British Journal of Dermatology, 2019, 180, e241.	1.4	0
70	Gender equity in epidemiology: a policy brief. Annals of Epidemiology, 2019, 35, 1-3.	0.9	12
71	Associations of pigmentary and naevus phenotype with melanoma risk in two populations with comparable ancestry but contrasting levels of ambient sun exposure. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1874-1885.	1.3	10
72	Patientsâ€™ Views About Skin Self-examination After Treatment for Localized Melanoma. JAMA Dermatology, 2019, 155, 914.	2.0	22

#	Article	IF	Citations
73	Risk attitudes and sun protection behaviour: Can behaviour be altered by using a melanoma genomic risk intervention?. Cancer Epidemiology, 2019, 61, 8-13.	0.8	6
74	MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort. The Lancet Child and Adolescent Health, 2019, 3, 332-342.	2.7	16
75	Relationship of Chromosome Arm 10q Variants toÂOccurrence of Multiple Primary Melanoma in theÂPopulation-Based Genes, Environment, andÂMelanoma (GEM) Study. Journal of Investigative Dermatology, 2019, 139, 1410-1412.	0.3	0
76	å¯¹é»'è‰²ç´ ç˜é•–ä¼é£Žé™©ä¿¡æ•ç„æƒ…æ„Ÿå'Œè¡Œä¸ºå½±. British Journal of Dermatology, 2019, 180, e258.	1.4	0
77	Exploring the emotional and behavioural reactions to receiving personalized melanoma genomic risk information: a qualitative study. British Journal of Dermatology, 2019, 180, 1390-1396.	1.4	14
78	The steadily growing problem of lentigo maligna and lentigo maligna melanoma in Australia: Populationâ€based data on diagnosis and management. Australasian Journal of Dermatology, 2019, 60, 118-125.	0.4	21
79	Cancer screening in Australia: future directions in melanoma, Lynch syndrome, and liver, lung and prostate cancers. Public Health Research and Practice, 2019, 29, .	0.7	5
80	GP attitudes to and expectations for providing personal genomic risk information to the public: a qualitative study. BJGP Open, 2019, 3, bjgpopen18X101633.	0.9	15
81	Molecular Epidemiology of Melanoma. , 2019, , 1-19.		0
82	Polyunsaturated fatty acids and risk of melanoma: A <scp>M</scp>endelian randomisation analysis. International Journal of Cancer, 2018, 143, 508-514.	2.3	18
83	Beyond country-specific incidence and mortality: the global burden of melanoma. British Journal of Dermatology, 2018, 178, 315-316.	1.4	9
84	Prognostic features for acral lentiginous melanoma. British Journal of Dermatology, 2018, 178, 311-312.	1.4	7
85	Validation of Questionnaire and Diary Measures of Time Outdoors Against an Objective Measure of Personal Ultraviolet Radiation Exposure. Photochemistry and Photobiology, 2018, 94, 815-820.	1.3	10
86	Follow-Up Recommendations after Diagnosis of Primary Cutaneous Melanoma: A Population-Based Study in New South Wales, Australia. Annals of Surgical Oncology, 2018, 25, 617-625.	0.7	18
87	A National Budget Impact Analysis of a Specialised Surveillance Programme for Individuals at Very High Risk of Melanoma in Australia. Applied Health Economics and Health Policy, 2018, 16, 235-242.	1.0	7
88	Development and Evaluation of a Telephone Communication Protocol for the Delivery of Personalized Melanoma Genomic Risk to the General Population. Journal of Genetic Counseling, 2018, 27, 370-380.	0.9	20
89	Distress, uncertainty, and positive experiences associated with receiving information on personal genomic risk of melanoma. European Journal of Human Genetics, 2018, 26, 1094-1100.	1.4	21
90	The interaction between vitamin D receptor polymorphisms and sun exposure around time of diagnosis influences melanoma survival. Pigment Cell and Melanoma Research, 2018, 31, 287-296.	1.5	13

#	Article	IF	Citations
91	Sensitivity of Preference-Based Quality-of-Life Measures for Economic Evaluations in Early-Stage Melanoma. JAMA Dermatology, 2018, 154, 52.	2.0	11
92	The Importance of Population-Based Estimates of Melanocytic Pathology. JAMA Dermatology, 2018, 154, 15.	2.0	1
93	Exercise as part of routine cancer care. Lancet Oncology, The, 2018, 19, e432.	5.1	8
94	The melanoma genomics managing your risk study: A protocol for a randomized controlled trial evaluating the impact of personal genomic risk information on skin cancer prevention behaviors. Contemporary Clinical Trials, 2018, 70, 106-116.	0.8	19
95	Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes. Journal of Investigative Dermatology, 2018, 138, 2398-2404.	0.3	9
96	Combining common genetic variants and non-genetic risk factors to predict risk of cutaneous melanoma. Human Molecular Genetics, 2018, 27, 4145-4156.	1.4	34
97	Sunscreen Use and Melanoma Risk Among Young Australian Adults. JAMA Dermatology, 2018, 154, 1001.	2.0	40
98	Melanomaâ€“role of the environment and genetics. Photochemical and Photobiological Sciences, 2018, 17, 1853-1860.	1.6	18
99	Why a randomized melanoma screening trial may be a good idea. British Journal of Dermatology, 2018, 179, 1227-1228.	1.4	3
100	Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies. Journal of Investigative Dermatology, 2018, 138, 2617-2624.	0.3	52
101	Clinical Oncology Society of Australia position statement on exercise in cancer care. Medical Journal of Australia, 2018, 209, 184-187.	0.8	254
102	Sustained long-term benefits of a psycho-educational intervention targeting fear of cancer recurrence in people at high risk of developing another melanoma: A randomised controlled trial.. Journal of Clinical Oncology, 2018, 36, 10082-10082.	0.8	1
103	Sun exposure and skin cancer, and the puzzle of cutaneous melanoma. Cancer Epidemiology, 2017, 48, 147-156.	0.8	96
104	Does personalized melanoma genomic risk information trigger conversations about skin cancer prevention and skin examination with family, friends and health professionals?. British Journal of Dermatology, 2017, 177, 779-790.	1.4	15
105	Shared decision making in Australia in 2017. Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen, 2017, 123-124, 17-20.	0.7	20
106	Increasing prevalence but not incidence of psoriasis in the U.K.. British Journal of Dermatology, 2017, 176, 568-569.	1.4	0
107	Germline Variation at CDKN2A and Associations with Nevus Phenotypes amongÂMembers of Melanoma Families. Journal of Investigative Dermatology, 2017, 137, 2606-2612.	0.3	18
108	Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma. Journal of Investigative Dermatology, 2017, 137, 2588-2598.	0.3	11

#	Article	IF	Citations
109	Functional melanomaâ€risk variant <scp>IRF</scp> 4 rs12203592 associated with Breslow thickness: a pooled international study of primary melanomas. British Journal of Dermatology, 2017, 177, e180-e182.	1.4	14
110	Association of Incident Amelanotic Melanoma With Phenotypic Characteristics, MC1R Status, and Prior Amelanotic Melanoma. JAMA Dermatology, 2017, 153, 1026.	2.0	19
111	Estimating the future health service burden of keratinocyte cancers in the U.K.. British Journal of Dermatology, 2017, 176, 1107-1108.	1.4	0
112	Poor Adherence to National Clinical Management Guidelines: A Population-Based, Cross-Sectional Study of the Surgical Management of Melanoma in New South Wales, Australia. Annals of Surgical Oncology, 2017, 24, 2080-2088.	0.7	31
113	Clinical Features Associated With Individuals at Higher Risk of Melanoma. JAMA Dermatology, 2017, 153, 23.	2.0	43
114	Diagnosis and clinical management of melanoma patients at higher risk of a new primary melanoma: A populationâ€based study in New South Wales, Australia. Australasian Journal of Dermatology, 2017, 58, 278-285.	0.4	12
115	A Pilot Randomized Controlled Trial of the Feasibility, Acceptability, and Impact of Giving Information on Personalized Genomic Risk of Melanoma to the Public. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 212-221.	1.1	44
116	Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma. Journal of Clinical Oncology, 2017, 35, 63-71.	0.8	66
117	Psychoeducational intervention for people at high risk of developing another melanoma: a pilot randomised controlled trial. BMJ Open, 2017, 7, e015195.	0.8	8
118	Abstract B15: Communicating information about personalised genomic risk of melanoma to family, friends, and health professionals. , 2017, , .		0
119	Economic evaluations of psychosocial interventions in cancer: a systematic review. Psycho-Oncology, 2016, 25, 1380-1392.	1.0	53
120	Psychometric properties of the Fear of Cancer Recurrence Inventory: an item response theory approach. Psycho-Oncology, 2016, 25, 832-838.	1.0	34
121	Nevus count associations with pigmentary phenotype, histopathological melanoma characteristics and survival from melanoma. International Journal of Cancer, 2016, 139, 1217-1222.	2.3	11
122	Protocol for a within-trial economic evaluation of a psychoeducational intervention tailored to people at high risk of developing a second or subsequent melanoma. BMJ Open, 2016, 6, e012153.	0.8	6
123	Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial. Journal of Clinical Oncology, 2016, 34, 4405-4414.	0.8	91
124	Public preferences for communicating personal genomic risk information: a focus group study. Health Expectations, 2016, 19, 1203-1214.	1.1	28
125	â€œMelanoma: Questions and Answers.â€•Development and evaluation of a psycho-educational resource for people with a history of melanoma. Supportive Care in Cancer, 2016, 24, 4849-4859.	1.0	19
126	Doctorsâ€™ recognition and management of melanoma patientsâ€™ risk: An Australian population-based study. Cancer Epidemiology, 2016, 45, 32-39.	0.8	1

#	Article	IF	Citations
127	Variants in autophagyâ€related genes and clinical characteristics in melanoma: a populationâ€based study. Cancer Medicine, 2016, 5, 3336-3345.	1.3	23
128	Physical Activity Correlates, Barriers, and Preferences for Women With Gynecological Cancer. International Journal of Gynecological Cancer, 2016, 26, 1530-1537.	1.2	21
129	Development and External Validation of a Melanoma Risk Prediction Model Based on Self-assessed Risk Factors. JAMA Dermatology, 2016, 152, 889.	2.0	53
130	Melanoma Epidemiology and Prevention. Cancer Treatment and Research, 2016, 167, 17-49.	0.2	111
131	Association of Interferon Regulatory Factor-4 Polymorphism rs12203592 With Divergent Melanoma Pathways. Journal of the National Cancer Institute, 2016, 108, djw004.	3.0	28
132	Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members ofÂMelanoma Families. Journal of Investigative Dermatology, 2016, 136, 1066-1069.	0.3	13
133	Randomised controlled trial of a psycho-educational intervention to reduce fear of cancer recurrence in people at high risk of developing another primary melanoma.. Journal of Clinical Oncology, 2016, 34, 10068-10068.	0.8	1
134	A pilot randomised controlled trial examining the feasibility, acceptability and impact of giving information on personalised genomic risk of melanoma to the public, for motivating preventive behaviours.. Journal of Clinical Oncology, 2016, 34, 1556-1556.	0.8	0
135	Abstract 1016: Variants in autophagy related genes and clinical characteristics in melanoma: a population-based study. , 2016, , .		0
136	Inherited variation at MC1R and ASIP and association with melanomaâ€specific survival. International Journal of Cancer, 2015, 136, 2659-2667.	2.3	27
137	Exploring the Potential Emotional and Behavioural Impact of Providing Personalised Genomic Risk Information to the Public: A Focus Group Study. Public Health Genomics, 2015, 18, 309-317.	0.6	15
138	Inherited Variation at MC1R and Histological Characteristics of Primary Melanoma. PLoS ONE, 2015, 10, e0119920.	1.1	22
139	Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma. JAMA Oncology, 2015, 1, 359.	3.4	164
140	Specialized Surveillance for Individuals at High Risk for Melanoma. JAMA Dermatology, 2015, 151, 178.	2.0	25
141	Genome-wide meta-analysis identifies five new susceptibility loci for cutaneous malignant melanoma. Nature Genetics, 2015, 47, 987-995.	9.4	218
142	Accuracy of Self-Reported Nevus and Pigmentation Phenotype Compared with Clinical Assessment in a Population-Based Study of Young Australian Adults. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 736-743.	1.1	15
143	Exposure to the 'Dark Side of Tanning' skin cancer prevention mass media campaign and its association with tanning attitudes in New South Wales, Australia. Health Education Research, 2015, 30, 336-346.	1.0	26
144	Inherited Genetic Variants Associated with Occurrence of Multiple Primary Melanoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 992-997.	1.1	36

#	Article	IF	Citations
145	The Melanoma care study: protocol of a randomised controlled trial of a psycho-educational intervention for melanoma survivors at high risk of developing new primary disease. BMC Psychology, 2015, 3, 23.	0.9	14
146	Clinical practice guidelines for identification, screening and follow-up of individuals at high risk of primary cutaneous melanoma: a systematic review. British Journal of Dermatology, 2015, 172, 33-47.	1.4	115
147	Sun Exposure and Melanoma Survival: A GEM Study. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 2145-2152.	1.1	26
148	Identification of a melanoma susceptibility locus and somatic mutation inTET2. Carcinogenesis, 2014, 35, 2097-2101.	1.3	41
149	Occupational sun exposure and risk of melanoma according to anatomical site. International Journal of Cancer, 2014, 134, 2735-2741.	2.3	29
150	Improving subjective perception of personal cancer risk: systematic review and metaâ€analysis of educational interventions for people with cancer or at high risk of cancer. Psycho-Oncology, 2014, 23, 613-625.	1.0	29
151	<scp>MITF</scp> E318K's effect on melanoma risk independent of, but modified by, other risk factors. Pigment Cell and Melanoma Research, 2014, 27, 485-488.	1.5	35
152	Accuracy of Self-Report of Nevus and Pigmentation Phenotype Compared to Clinical Assessment in Young Australian Adults. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 566.1-566.	1.1	0
153	Contribution of MC1R Genotype and Novel Common Genomic Variants to Melanoma Risk Prediction. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 566-567.	1.1	6
154	Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. Hereditary Cancer in Clinical Practice, 2014, 12, 20.	0.6	45
155	The Effect on Melanoma Risk of Genes Previously Associated With Telomere Length. Journal of the National Cancer Institute, 2014, 106, .	3.0	109
156	Risk Prediction Models for Incident Primary Cutaneous Melanoma. JAMA Dermatology, 2014, 150, 434.	2.0	74
157	MC1Rgenotype as a predictor of early-onset melanoma, compared with self-reported and physician-measured traditional risk factors: an Australian case-control-family study. BMC Cancer, 2013, 13, 406.	1.1	30
158	A variant in FTO shows association with melanoma risk not due to BMI. Nature Genetics, 2013, 45, 428-432.	9.4	111
159	Association between putative functional variants in the <scp>PSMB</scp>9 gene and risk of melanoma â€“ reâ€analysis of published melanoma genomeâ€wide association studies. Pigment Cell and Melanoma Research, 2013, 26, 392-401.	1.5	5
160	Association between functional polymorphisms in genes involved in the MAPK signaling pathways and cutaneous melanoma risk. Carcinogenesis, 2013, 34, 885-892.	1.3	10
161	Hormonal, Metabolic, and Inflammatory Profiles and Endometrial Cancer Risk Within the EPIC Cohortâ€”A Factor Analysis. American Journal of Epidemiology, 2013, 177, 787-799.	1.6	119
162	MC1R genotypes and risk of melanoma before age 40 years: A populationâ€based caseâ€controlâ€family study. International Journal of Cancer, 2012, 131, E269-81.	2.3	32

#	Article	IF	Citations
163	Genome-wide association study identifies novel loci predisposing to cutaneous melanomaâ€. Human Molecular Genetics, 2011, 20, 5012-5023.	1.4	187
164	Genome-wide association study identifies three new melanoma susceptibility loci. Nature Genetics, 2011, 43, 1108-1113.	9.4	230
165	Pathway-Based Analysis of a Melanoma Genome-Wide Association Study: Analysis of Genes Related to Tumour-Immunosuppression. PLoS ONE, 2011, 6, e29451.	1.1	18
166	Early-life sun exposure and risk of melanoma before age 40Âyears. Cancer Causes and Control, 2011, 22, 885-897.	0.8	43
167	Sunbed use during adolescence and early adulthood is associated with increased risk of earlyâ€onset melanoma. International Journal of Cancer, 2011, 128, 2425-2435.	2.3	194
168	Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK. Journal of Medical Genetics, 2011, 48, 266-272.	1.5	41
169	A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature, 2011, 480, 99-103.	13.7	413
170	Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3. Nature Genetics, 2011, 43, 1114-1118.	9.4	140
171	Anthropometric measures and epithelial ovarian cancer risk in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2010, 126, 2404-2415.	2.3	68
172	Physical Activity and Gynecologic Cancer Prevention. Recent Results in Cancer Research, 2010, 186, 159-185.	1.8	46
173	Methodological Challenges in the Application of the Glycemic Index in Epidemiological Studies Using Data from the European Prospective Investigation into Cancer and Nutrition. Journal of Nutrition, 2009, 139, 568-575.	1.3	61
174	Physical Activity and Ovarian Cancer Risk: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 351-354.	1.1	70
175	Self-reported Confidence in Recall as a Predictor of Validity and Repeatability of Physical Activity Questionnaire Data. Epidemiology, 2009, 20, 433-441.	1.2	29
176	Population-based, Case-Control-Family Design to Investigate Genetic and Environmental Influences on Melanoma Risk: Australian Melanoma Family Study. American Journal of Epidemiology, 2009, 170, 1541-1554.	1.6	46
177	The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Research and Treatment, 2009, 113, 567-576.	1.1	88
178	Total dietary carbohydrate, sugar, starch and fibre intakes in the European Prospective Investigation into Cancer and Nutrition. European Journal of Clinical Nutrition, 2009, 63, S37-S60.	1.3	87
179	Dietary glycaemic index and glycaemic load in the European Prospective Investigation into Cancer and Nutrition. European Journal of Clinical Nutrition, 2009, 63, S188-S205.	1.3	52
180	Common sequence variants on 20q11.22 confer melanoma susceptibility. Nature Genetics, 2008, 40, 838-840.	9.4	209

#	Article	IF	Citations
181	Validity and repeatability of the EPIC physical activity questionnaire: a validation study using accelerometers as an objective measure. International Journal of Behavioral Nutrition and Physical Activity, 2008, 5, 33.	2.0	153
182	Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. British Journal of Sports Medicine, 2008, 42, 636-647.	3.1	260
183	Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer, 2008, 15, 485-497.	1.6	228
184	The association between dietary macronutrient intake and the prevalence of the metabolic syndrome. British Journal of Nutrition, 2008, 100, 400-407.	1.2	33
185	Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocrine-Related Cancer, 2007, 14, 755-767.	1.6	104
186	Plasma Adiponectin Levels and Endometrial Cancer Risk in Pre- and Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 255-263.	1.8	191
187	Dietary Carbohydrates, Glycemic Index, Glycemic Load, and Endometrial Cancer Risk within the European Prospective Investigation into Cancer and Nutrition Cohort. American Journal of Epidemiology, 2007, 166, 912-923.	1.6	53
188	Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; Results from the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2007, 120, 2656-2664.	2.3	96
189	Physical activity and risk of endometrial cancer: The European prospective investigation into cancer and nutrition. International Journal of Cancer, 2007, 121, 347-355.	2.3	89
190	Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. International Journal of Cancer, 2007, 121, 368-376.	2.3	166
191	Risk of endometrial cancer in relationship to cigarette smoking: Results from the EPIC study. International Journal of Cancer, 2007, 121, 2741-2747.	2.3	46
192	Physical activity and endometrial cancer risk: a review of the current evidence, biologic mechanisms and the quality of physical activity assessment methods. Cancer Causes and Control, 2007, 18, 243-258.	0.8	72
193	Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. Cancer Causes and Control, 2007, 18, 399-413.	0.8	148
194	Physical activity and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition Cohort. International Journal of Cancer, 2006, 119, 2389-2397.	2.3	62
195	Noninvasive Ventilation. New England Journal of Medicine, 2004, 351, 1257-1259.	13.9	3
196	Can polyclonal intravenous immunoglobulin limit cytokine mediated cerebral damage and chronic lung disease in preterm infants?. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2004, 89, 5F-8.	1.4	13
197	Improved outcomes for very low birthweight infants: evidence from New Zealand national population based data. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2003, 88, 23F-28.	1.4	83
198	Outcomes for high risk New Zealand newborn infants in 1998-1999: a population based, national study. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2003, 88, 15F-22.	1.4	45

#	Article	IF	Citations
199	Polyclonal intravenous immunoglobulin to prevent brain injury in preterm infants. Lancet, The, 2002, 359, 1522.	6.3	3
200	Alarm settings for the Marquette 8000 pulse oximeter to prevent hyperoxic and hypoxic episodes. Journal of Paediatrics and Child Health, 1999, 35, 159-162.	0.4	0
201	Barriers and Facilitators for Population Genetic Screening in Healthy Populations: A Systematic Review. Frontiers in Genetics, 0, 13, .	1.1	10